Nanosuspension Stabilization for Poorly Soluble Drug Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical dosage forms with low water solubility face challenges in maintaining bioavailability and uniformity due to particle size issues, leading to unpredictable absorption and solubility profiles, especially for orally administered drugs with limited solubility.
Innovation Solution
The development of nanosuspensions comprising drug particles with sizes less than 1 μm, stabilized with water-soluble surfactants and polymers, which are processed into solid dosage forms using fixed-geometry fluid processors and coated with inert supports to maintain particle size and enhance solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If particle size is reduced to enhance solubility and bioavailability, then solubility rate improves, but particle stability deteriorates due to agglomeration and electrostatic effects
Solution Approach 1:
The patent introduces stabilizers as intermediary substances that adsorb onto the surface of micronized particles to prevent agglomeration and electrostatic effects. These stabilizers act as mediators between the small particles and the surrounding environment, maintaining particle dispersion and stability during handling and storage while preserving the enhanced solubility benefits of reduced particle size.
2Manufacturing precision
If smaller particles are used to increase surface area and solubilization rate, then bioavailability improves, but handling difficulty increases due to poor flowability
Solution Approach 1:
Stabilizers serve as intermediary agents that improve the flowability and handling characteristics of micronized particles. By adsorbing onto particle surfaces, they reduce interparticle friction and electrostatic attraction, enabling small particles to flow and blend effectively in manufacturing processes while maintaining their high surface area and solubilization rate.
3Manufacturing precision
If particle size is reduced below 20 μm to enhance bioavailability, then solubility improves, but particle size increases during storage due to agglomeration
Solution Approach 1:
The patent applies preliminary anti-action by incorporating stabilizers during the micronization process to prevent agglomeration before it occurs during storage. The stabilizers are pre-adSORBED onto particle surfaces, creating a protective barrier that actively counteracts the tendency of small particles to agglomerate over time, thereby maintaining the intended particle size distribution throughout the storage period.
4Ease of operation
If micronized particles are blended with larger particles to improve flowability, then handling improves, but blend uniformity deteriorates
Solution Approach 1:
The patent applies homogeneity by coating all particles with stabilizers to create a uniform surface property across different particle sizes. This standardized surface treatment ensures that both micronized and larger particles exhibit similar flow characteristics and interparticle interactions, enabling effective blending and uniform distribution in formulations without sacrificing the bioavailability benefits of the micronized component.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in improved bioavailability and reproducible solubility profiles for poorly soluble drugs, maintaining supersaturation and preventing agglomeration, thereby enhancing therapeutic efficacy.
Implementation Method 1
particles of a pharmaceutically active ingredient that have been subjected to particle size reduction using a fixed-geometry fluid processor
Implementation Method 2
a water-soluble surfactant and a water-soluble polymer... preventing agglomeration
Implementation Method 3
maintaining supersaturation
Data Source
AI summary
A pharmaceutical composition and method of producing supersaturated stabilized nanoparticles of poorly soluble drugs having average sizes less than 1 μm, or less than 800 nm, or less than 500 nm, comprising at least one pharmaceutically active ingredient, a hydrophilic polymer, a water-soluble surfactant, and subsequently stabilized by ionic polymers.